Abstract:Abstract The incidence and mortality rates of hepatocellular carcinoma caused by metabolic dysfunction-associated fatty liver disease (MAFLD) have been increasing in recent decades, emphasizing the urgent need for new therapeutic approaches. Emerging evidence suggests that approximately 80% of super-enhancer RNAs (seRNAs) undergo selective m6A modifications. seRNA and m6A modifications have been implicated in the progression of various cancers, making them potential targets for therapeutic intervention. Based on our previous research, we hypothesize that the lack of m6A modification on the super-enhancer of CCL4 may contribute to the reduced expression of the CCL4 gene in HCC.To validate our hypothesis, we employ nano-chromatin immunoprecipitation combined with high-throughput sequencing (nano-ChIP-seq), m6A-seq (m6A-seq), single-cell RNA sequencing (scRNA-seq) on multiple models including clinical samples, cell lines, and mouse models. Interestingly, we have made a significant discovery that overexpression of CCL4 in tumor cells enhances the infiltration of CD8+ T cells, which are crucial for anti-tumor immune responses. In contrast, normal tissue cells undergo m6A modification on the CCL4 seRNAs, while this modification is notably absent in cancerous tissue. Consequently, the reduced expression of CCL4 could impair the tumor-killing capabilities of CD8+ T cells and facilitate immune evasion by the tumor.Furthermore, our results shed light on the underlying molecular mechanisms involving super-enhancers and m6A modifications in the regulation of immune escape in MAFLD HCC. We identify the specific super-enhancer and downstream regulatory genes influenced by m6A modification in MAFLD-associated HCC, providing valuable insights and novel targets for the treatment of this condition. Citation Format: Liangliang Xu. Super-enhancer-related m6A modification promotes immune escape in hepatocellular carcinoma associated with metabolic dysfunction-associated fatty liver disease via CCL4 signaling pathway inhibition [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 2637.

Insight into the regulatory mechanism of m 6 A modification: From MAFLD to hepatocellular carcinoma

Interaction Between N6-methyladenosine Modification and the Tumor Microenvironment in Colorectal Cancer

The emerging roles of N6-methyladenosine RNA methylation in human cancers

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

The Emerging Molecular Mechanism of M6a Modulators in Tumorigenesis and Cancer Progression

Roles of N6‐methyladenosine epitranscriptome in non‐alcoholic fatty liver disease and hepatocellular carcinoma

Role of m6A RNA methylation in the development of hepatitis B virus-associated hepatocellular carcinoma.

Dysregulated m6A modification promotes lipogenesis and development of non-alcoholic fatty liver disease and hepatocellular carcinoma

The emerging roles of m6A modification in liver carcinogenesis

Circular RNAs, Noncoding RNAs, and N6-methyladenosine Involved in the Development of MAFLD

Abstract 2637: Super-enhancer-related m6A modification promotes immune escape in hepatocellular carcinoma associated with metabolic dysfunction-associated fatty liver disease via CCL4 signaling pathway inhibition

Mechanisms of RNA N 6 -Methyladenosine in Hepatocellular Carcinoma: From the Perspectives of Etiology.

New roles of N6-methyladenosine methylation system regulating the occurrence of non-alcoholic fatty liver disease with N6-methyladenosine-modified MYC

New horizons for the role of RNA N6-methyladenosine modification in hepatocellular carcinoma

RNA modifications in the progression of liver diseases: from fatty liver to cancer

Comprehensive analysis of m6A modification in immune infiltration, metabolism and drug resistance in hepatocellular carcinoma

Mettl3-m6A-YTHDF1 axis promotion of mitochondrial dysfunction in metabolic dysfunction-associated steatotic liver disease

Dysregulated N6-methyladenosine (m6A) processing in hepatocellular carcinoma

Landscape of m6A RNA methylation regulators in liver cancer and its therapeutic implications

Targeting non-coding RNAs and N 6 -methyladenosine modification in hepatocellular carcinoma

The Crucial Roles of N6-methyladenosine (m6a) Modification in the Carcinogenesis and Progression of Colorectal Cancer